Also known as: NCCN
Cocrystal Pharma advanced CDI-988 in a Phase 1b norovirus study and received FDA Fast Track designation. Nuvation Bio reported $18.5 million in IBTROZI net product revenues and presented updated TRUST trial data. Nautilus Biotechnology progressed its proteomics platform toward commercialization, maintaining a cash runway through 2027.
ImmunityBio's Q1 2026 product revenue rose 168% to $44.2 million, beating estimates, while the GAAP net loss widened to $632.8 million. The company is advancing a Phase 2 NHL trial and an sBLA for BCG-naïve NMIBC.
A large clinical trial found that adding apalutamide to hormone therapy before and after prostate cancer surgery improves outcomes for high-risk patients. NHS England will roll out SABR radiotherapy requiring only five sessions, and new ctDNA and robotic biopsy technologies are advancing prostate cancer care.
Four biomarkers—MMR, HER2, PD-L1, and Claudin 18.2—are now validated for advanced esophageal cancer, guiding immunotherapy and targeted treatment decisions. Checkpoint inhibitors show clear benefit in MSI-H and PD-L1-positive subgroups, with long-term survival observed. NCCN guidelines recommend broad testing to personalize therapy.
Gilead Sciences reported Q1 2026 total product sales of $6.9 billion, up 5% year over year, with HIV revenue growing 10% to $5.0 billion. The company raised its full-year 2026 base business revenue guidance by $400 million to $29.4–$29.8 billion. Non-GAAP diluted EPS was $2.03, up 12%, while the company advanced its oncology and cell therapy pipeline.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Research found variation in guideline-concordant colorectal cancer care across hospitals and systems, while a separate study highlighted the role of specialized cancer nurses in reducing distress and improving support.
Compass Therapeutics reported mixed Phase 2/3 data for tovecimig in biliary tract cancer and plans to meet with the FDA for a BLA discussion. The study met its primary ORR endpoint (17% vs 5%), while PFS and OS data are due late this quarter.
A study in stage 3 dMMR colon cancer found that atezolizumab plus chemotherapy after surgery cut recurrence and death risk by 50%. The trial enrolled 712 patients and the regimen is now included in treatment guidelines.
The National Comprehensive Cancer Network has updated its bladder cancer guidelines to include ImmunityBio's Anktiva plus BCG for BCG-unresponsive papillary-only disease. The Category 2A recommendation expands treatment options beyond the drug's initial FDA approval for carcinoma in situ. ImmunityBio also announced its pivotal trial is adequately powered and European distribution partnerships to expand global access.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07781800 |
Navigation Interventions for Patients With Breast Cancer and High-risk Social Determinants of Health |
NOT_YET_RECRUITING | NA |
| NCT07549139 |
Overcoming Racial Disparities in Screening Mammography |
NOT_YET_RECRUITING | NA |
| NCT07146646 |
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer |
RECRUITING | PHASE2 |
| NCT07030400 |
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma |
RECRUITING | |
| NCT06682390 |
Role of Race in Nutritional Approach in Men on ADT |
RECRUITING | NA |
| NCT06650579 |
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial |
RECRUITING | PHASE3 |
| NCT06483100 |
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance |
RECRUITING | PHASE2 |
| NCT06463457 |
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06396598 |
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT06202820 |
CV CARE: CardioVascular Care in PC Patients |
RECRUITING | NA |
